DC-XYLEM
Manchester City Football Club’s global community program, Cityzens Giving, and global water technology leader, Xylem (NYSE: XYL) are calling on football fans to vote for their top project as the Water Heroes Academy returns for a second year. From November 22 to December 5, fans from around the world can vote for one of five new football and water projects from young leaders working to tackle global water issues in Buenos Aires, Cape Coast, Kuala Lumpur, Melbourne, and Mexico City.
Young leaders involved in this year’s program are using the power of football to provide essential education on water, sanitation, and hygiene in a bid to tackle water challenges specific to their communities. Projects include improving access to safe water in underserved communities in Buenos Aires and Cape Coast, building flood-resilient communities in Mexico City and Kuala Lumpur, and advancing water sustainability education in Melbourne.
The top-voted project will win the opportunity for young leaders to experience a once-in-a-lifetime trip to the Etihad Stadium. There, they will learn more about water challenges and solutions, and receive further training on how they can help improve the health and well-being of young people in their communities. Each of the Water Heroes Academy projects will receive funding, educational tools, training, and mentoring from Xylem and Cityzens Giving, providing young leaders the resources needed to create their own unique programs going forward.
The Water Heroes Academy is a joint initiative by Cityzens Giving and Xylem that aims to positively impact 20,000 young people over the next four years. Last year, the program engaged more than 75 young water leaders and delivered vital education to more than 6,000 young people in São Paulo, Mumbai, Cape Town, New York City, and Shanghai. Mumbai was the winning project, having received thousands of fan votes. Delivered in collaboration with Magic Bus India Foundation, the project aimed to improve local access to safe water, sanitation, and hygiene.
“In my community, many children aren’t able to access clean water in school, which means they fall ill and can no longer attend class due to poor health,” said Varsha, a Young Leader from the Mumbai Team. “The opportunity to better the lives of people in my community through awareness and education motivates me. I’m incredibly proud to contribute to the development of my community and make a positive difference in the lives of young people through my experience with the Water Heroes Academy.”
“We’re thrilled to be working with Xylem to spotlight five more of our inspiring Water Heroes Academy projects around the world, celebrating our Cityzens Giving young leaders who are all making such an important impact in their local communities,” said Tom Pitchon, Global Foundation Director at City Football Group. “It was fantastic to welcome our Mumbai water heroes to Manchester last season, and we look forward to welcoming young leaders from the top-voted project this year, so vote now!”
“We are incredibly proud of our partnership with Manchester City and the global network of young water leaders created through the Water Heroes Academy program,” said Randolf Waters, Senior Director of Global Partnerships & Branding at Xylem. “In spotlighting the work these incredible water leaders are doing locally, we hope to inspire more young people to get involved in tackling water issues and drive positive change on a global level. I encourage football fans to get behind our water heroes and vote for their favorite project.”
To hear the story of each project and to vote for your top project, visit: www.mancity.com/waterheroes
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water secure. Join us at www.xylem.com.
About Manchester City Football Club
Manchester City FC is an English Premier League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has since then gone onto win the European Cup Winners’ Cup, eight League Championship titles, including six Premier League titles (2012, 2014, 2018, 2019, 2021, 2022), and six FA Cups. Manchester City FC is one of 12 clubs comprising the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.
Under manager Pep Guardiola, one of the most highly-decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.
For more information, please visit www.mancity.com.
About Cityzens Giving
Cityzens Giving is an award-winning global programme, empowering young leaders to use football as a tool to uplift the health of children and young people in cities around the world. Projects are run by young people for young people, with fans, staff and partners across City Football Group getting involved in diverse ways, from volunteering and fundraising to donating and having a say in how projects are supported. In addition to long-term grant funding, young leaders access training in community football and leadership from our Club community coaches and networking opportunities with other community football projects worldwide. This includes face to face training in country, remote support, and regular global gatherings to facilitate the flow of know-how and learning. Each year, Cityzens Giving supports over 1,000 Young Leaders to positively impact the health of thousands of young people in 25 cities across the globe.
For more information, please visit https://www.mancity.com/community/global-projects.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005464/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom